Melbourne Melanoma Project committed to improving the diagnosis and early detection of melanoma.

Clinicopathological factors associated with death from thin (? 1·00 mm) melanoma

Researchers conducted a large, nested case–case study including data from the population-based Queensland Cancer Registry, Australia in order to recognize the clinicopathological factors associated with fatal thin melanomas.

Spartalizumab Plus Dabrafenib/Trametinib Impresses in BRAF+ Melanoma With Poor Prognosis

A triplet combining the PD-1 inhibitor spartalizumab with dabrafenib (Tafinlar) and trametinib (Mekinist) led to a 12-month overall survival (OS) rate of 86.1% for patients with previously untreated advanced BRAF V600–mutant melanoma, according to pooled findings from the phase III COMBI-i trial presented during the 16th International Congress of the Society for Melanoma Research.1

First-in-Human Trial for Tebentafusp In Advanced Melanoma Shows Promising Safety Profile

Findings from the first-in-human trial evaluating tebentafusp (IMCgp100), a TCR–CD3 bispecific, in patients with advanced melanoma show tebentafusp not only working but showing a favorable safety profile, according to Alexander N. Shoushtari, MD.

Forgot to apply sunscreen? There’s a vending machine for that

In a city with a rate of melanoma higher than the national average, a new sun smart tactic is being trialled which will see machines that dispense sunscreen installed at local beaches and parks.

Posted in Melanoma News, Patients, Latest News